Beijing Konruns Pharmaceutical Co.,Ltd.
XSSC:603590 주식 보고서
Beijing Konruns PharmaceuticalLtd 대차 대조표 상태 Beijing Konruns PharmaceuticalLtd 의 총 주주 지분은 CN¥3.5B 이고 총 부채는 CN¥204.7M, 이는 부채 대 자기자본 비율을 5.8% 로 가져옵니다. 총자산과 총부채는 각각 CN¥4.0B 및 CN¥478.6M 입니다. Beijing Konruns PharmaceuticalLtd 의 EBIT는 CN¥89.7M 이며 이자보상배율은 -6.2 입니다. CN¥640.3M 의 현금 및 단기 투자금을 보유하고 있습니다.
주요 정보 이자 보상 비율 -6.2x 현금 CN¥640.32m 주식 CN¥3.52b 총 부채 CN¥478.64m 총 자산 CN¥4.00b
최근 재무 상태 업데이트
모든 업데이트 표시
Third quarter 2024 earnings released: EPS: CN¥0.22 (vs CN¥0.36 in 3Q 2023) Oct 30
Investor sentiment improves as stock rises 23% Sep 30
Beijing Konruns Pharmaceutical Co.,Ltd. to Report Q3, 2024 Results on Oct 30, 2024 Sep 30
Second quarter 2024 earnings released: EPS: CN¥0.23 (vs CN¥0.43 in 2Q 2023) Aug 28
Beijing Konruns Pharmaceutical Co.,Ltd. to Report First Half, 2024 Results on Aug 28, 2024 Jun 28
First quarter 2024 earnings released: EPS: CN¥0.27 (vs CN¥0.16 in 1Q 2023) Apr 27
Beijing Konruns Pharmaceutical Co.,Ltd., Annual General Meeting, May 16, 2024 Apr 27
Full year 2023 earnings released: EPS: CN¥0.96 (vs CN¥0.65 in FY 2022) Apr 09
Beijing Konruns Pharmaceutical Co.,Ltd. to Report Q1, 2024 Results on Apr 26, 2024 Mar 29
Investor sentiment deteriorates as stock falls 18% Feb 05
Beijing Konruns Pharmaceutical Co.,Ltd. to Report Fiscal Year 2023 Results on Apr 26, 2024 Dec 29
Beijing Konruns Pharmaceutical Co.,Ltd. to Report Q3, 2023 Results on Oct 28, 2023 Sep 30
Second quarter 2023 earnings released: EPS: CN¥0.43 (vs CN¥0.22 in 2Q 2022) Aug 01
Beijing Konruns Pharmaceutical Co.,Ltd. to Report First Half, 2023 Results on Aug 01, 2023 Jun 28
Investor sentiment deteriorates as stock falls 16% Jun 07
First quarter 2023 earnings released: EPS: CN¥0.16 (vs CN¥0.30 in 1Q 2022) Apr 26
Now 21% undervalued Dec 14
Less than half of directors are independent Nov 16
Investor sentiment improved over the past week Nov 05
Third quarter 2022 earnings released Oct 27
Investor sentiment improved over the past week May 25
Less than half of directors are independent Apr 27
Third quarter 2021 earnings released: EPS CN¥0.24 (vs CN¥0.25 in 3Q 2020) Oct 26
Second quarter 2021 earnings released: EPS CN¥0.22 (vs CN¥0.44 in 2Q 2020) Aug 24
First quarter 2021 earnings released: EPS CN¥0.41 (vs CN¥0.20 in 1Q 2020) Apr 30
Full year 2020 earnings released: EPS CN¥1.15 (vs CN¥1.66 in FY 2019) Mar 23
Beijing Konruns Pharmaceutical Co.,Ltd. to Report Fiscal Year 2020 Results on Mar 23, 2021 Jan 22
New 90-day low: CN¥34.99 Jan 14
New 90-day low: CN¥36.29 Dec 24
New 90-day low: CN¥37.52 Nov 11
New 90-day low: CN¥38.43 Oct 23
Third quarter earnings released Oct 20
Beijing Konruns Pharmaceutical Co.,Ltd. to Report Q3, 2020 Results on Oct 20, 2020 Oct 19
Beijing Konruns Pharmaceutical Co.,Ltd. announced that it expects to receive CNY 1.0563854 billion in funding from CBC Group and another investor Jul 17
재무 상태 분석
단기부채: 603590 의 단기 자산 ( CN¥1.1B )이 단기 부채 ( CN¥319.5M ).
장기 부채: 603590 의 단기 자산( CN¥1.1B )이 장기 부채 ( CN¥159.2M ).
부채 대 자본 내역 및 분석
부채 수준: 603590 총 부채보다 더 많은 현금을 보유하고 있습니다.
부채 감소: 603590 의 부채 대 자기자본 비율은 지난 5년간 0% 에서 5.8% 로 증가했습니다.
부채 범위: 603590 의 부채는 영업 현금 흐름 ( 80.5% )에 의해 잘 충당 되었습니다.
이자 보장: 603590 지불하는 것보다 더 많은 이자를 벌기 때문에 이자 지불 보장은 문제가 되지 않습니다.
Simply Wall St™ Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.
{"enabled":true,"variant":{"name":"control","enabled":true,"feature_enabled":true,"featureEnabled":true},"flagsReady":true,"flagsError":null}